TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of asthma, and presently has reversibility over pre-bronchodilator forced expiratory volume in 1 second (FEV1) of ≥ 20% at screening~* Percent of predicted FEV1 ≥ 40% and ≤ 80% at screening~* Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent~* Ongoing asthma symptoms with asthma control questionnaire (ACQ) composite score at screening and baseline ≥ 1.5 points~Exclusion Criteria:~* History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma~* History of allergic bronchopulmonary aspergillosis~* Respiratory infection within 4 weeks of screening or 1 week of baseline visit~* Subject has known history of Crohn's disease~* Subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol~* Subject has previously used any anti-interleukin-17 (IL17) biologic therapy~* Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study~* Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile~* Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)~* Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by subcutaneous injection on day 1, week 1, week 2 and every 2 weeks thereafter for 24 weeks.
- Brodalumab 210 mg (Type: EXPERIMENTAL): Participants received 210 mg brodalumab administered by subcutaneous injection on day 1, week 1, week 2, and every 2 weeks thereafter for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Implementation of a Tool to Identify Social Weaknesses in the Cancer Care Pathway

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed for cancer (solid or hematological) since 15 days maximum~* Age over 18 years~* Affiliated with or entitled to a social security scheme~Exclusion Criteria:~* Refusal to participate~* Patient unable to understand the study process~* Patient with documented history of cognitive or psychiatric disorders.~* Patient under tutorship or curatorship~* Patient not understanding French

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with cancer (Type: None): Patient with cancer will be included. They will have to answer at DEFCO tool.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* History of chronic plaque psoriasis vulgaris, for at least six months.~* ≥10% body surface affected~* Age 18 or greater.~* Concomitant, chronic, but well-controlled medical conditions such as hypertension are allowable.~* No treatment with topical steroids for at least 2 weeks prior to entering the study~* No treatment with systemic therapies, including etretinate, UVB, PUVA, or cyclosporine, other biologics 4 weeks prior to entering the study. However, if a patient is considered to be unstable, or would deteriorate clinically if the systemic agent is ceased (eg efalizumab), a shorter washout period may be considered, and would be documented in the patient charts.~* Patients who receive a stable dose of methotrexate (defined as \<15mg/week for 4 months or greater) for psoriatic arthritis may be included.~Exclusion Criteria:~* Subjects who do not meet the above criteria, or who meet any of the following criteria:~  * Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis.~ * PHOTOSENSITIVITY: Hypersensitivity to sunlight or UVB light of any type; history of Lupus, PMLE, or any disease known to be worsened by UV light exposure~ * A history of non-melanoma skin cancer may be acceptable, and in this situation, the patient will be carefully evaluated.~ * Poorly controlled medical conditions of any kind.~ * Any medical condition that, in the opinion of the Investigator, would jeopardize the health or well being of the patient during the course of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NB-UVB (Type: OTHER): Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2409021 Formulations in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy males or surgically sterile or postmenopausal females, as determined by medical history and physical examination~* Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m\^2)~* Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator~Exclusion Criteria:~* Have known allergies to LY2409021, related compounds or any components of the formulation, or history of significant atopy~* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have known or ongoing psychiatric disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Part A: LY2409021 Capsule (Type: EXPERIMENTAL): Single oral dose of LY2409021 capsule in one of three study periods.
- Part A: LY2409021 Tablet Pre-commercial (Type: EXPERIMENTAL): Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
- Part A: LY2409021 Tablet Commercial (Type: EXPERIMENTAL): Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
- Part B: LY2409021 Capsule (Type: EXPERIMENTAL): Single oral dose of LY2409021 capsule in one of two study periods.
- Part B: LY2409021 Tablet Commercial (Type: EXPERIMENTAL): Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient will undergo PCI for diagnostic and/or therapeutic purposes with a procedure that uses anticoagulation before the instrumentation and reversal of anticoagulation immediately after the procedure.~2. Male or female patients of any race, aged 18-80 years old.~3. The patient will be anti-coagulated with unfractionated heparin.~4. The patient is medically stable and physically and mentally able to participate in this study.~5. The patient has given written informed consent to participate in this study after fully understanding the implications and constraints of the protocol.~Exclusion Criteria:~1. The patient requires emergency surgery under conditions which prevent compliance with this protocol or which might cause unacceptable risk to the patient.~2. The patient requires any concomitant surgical procedures (e.g., carotid artery, CABG) during the PCI.~3. The patient has received any investigational drug within 30 days of study enrollment, or has had any prior exposure to PMX-60056.~4. The patient has any condition or abnormality which may, in the opinion of the Investigator, compromise the safety of the patient.~5. The patient is pregnant or breast feeding.~6. The patient is of childbearing potential and not under adequate contraceptive protection.~7. The patient has a history of clinically significant hematologic disease including heparin-induced thrombocytopenia, bleeding disorders, or platelet count \<100,000.~8. Severe impaired hepatic function (SGOT, SGPT \>2 x ULN).~9. History of AIDS, ± HIV.~10. History of allergy to heparin (beef or pig), protamine, or salmon.~11. History of chronic alcohol or drug abuse within the last one year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Heparin and PMX-60056 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Micro-Electrodes Implanted in a Human Nerve

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age and less than 65 years of age~* amputations~* peripheral nerve injury~* twelve participants for the 30 day implantation/physiological experimentation study~* three participants for the acute surgical implantation part of the study~Exclusion Criteria:~* incarceration~* pregnancy~* inability to consent~* psychiatric comorbidity~* increase the risk of adverse effects of general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Acute surgical implantation (Type: EXPERIMENTAL): The investigators will conduct three acute surgeries where a Utah slanted Electrode Array (USEA) will be implanted in volunteers who are about to undergo limb amputations. These acute implantations will provide the PI with human surgical experience in implanting USEAs and evaluating the containment system the investigators will be using to immobilize the implanted USEA in the nerve.
- Implantation of a Utah Electrode Array (Type: EXPERIMENTAL): The arm which has been amputated or has peripheral nerve trauma. Intervention include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about device feasibility and nerve stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Piloting Acute Care to Primary Care Linkage of Safety Net Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* Admitted to Harborview Medical Center with injuries sufficiently severe enough to require inpatient admission~* Experienced a traumatic injury~* Exhibits symptoms of PTSD while in the hospital ward~* Low-income~Exclusion Criteria:~* History of head, spinal, or other injury that may prevent participation in the ward interview~* Requires immediate intervention due to conditions such as self-inflicted injury, active psychosis, or active mania~* Currently incarcerated~* Likely to face criminal charges~* Lives outside of the state of Washington~* Not low-income

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stepped care (Type: EXPERIMENTAL): Combination of behavioral therapy and drug therapy
- Standard care provided to injured trauma survivors (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nesiritide in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Candidates for enrollment in this clinical trial are limited to adult patients (age\>21) diagnosed with chronic heart failure \> one year who are managed by heart failure specialists at the University of Chicago. Patients primarily managed by physicians other than the investigators will be enrolled with the concurrence of the treating physician. Study patients are characterized as high risk by fulfilling one or more of the following criteria:~1. Refractory class III or IV heart failure despite optimal medical therapy by a heart failure specialist: Angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-adrenergic blockers (BB), spironolactone (spiro), digoxin (dig), diuretics, and calcium channel blockers (CCB).~2. Frequent hospitalizations or ER visits (\>1/month on average).~Additionally, patients must be capable of giving informed consent and have adequate social supports to manage chronic, continuous IV infusion therapy with the assistance of home care nursing and the study coordinator.~Exclusion Criteria:~1. Nesiritide infusion \>24 hours in the previous 30 days.~2. Stable chronic heart failure or NYHA Class I or II.~3. Aortic stenosis greater than mild degree as determined by echocardiogram or catheterization.~4. Hypertrophic cardiomyopathy with an outflow tract gradient.~5. Isolated right heart failure (cor pulmonale).~6. Unstable coronary syndrome or myocardial infarction\< 3 months prior to enrollment.~7. Chronic hypotension with systolic blood pressure \< 80 mmHg.~8. Terminal noncardiovascular illness with life expectancy \<6 months. Moribund patients will not be considered for enrollment.~9. Active substance abuse.~10. Inadequate social support.~11. Contraindication to long term IV access.~12. Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Rome III criteria for IBS and have no red flags.~* Must have had a colonoscopy within the previous 5 years to exclude inflammatory or other bowel disease~* Be fluent and literate in English~* Must either be of non-childbearing potential or agree to utilize approved birth control for the duration of the study~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening.~* Any other diagnosis to explain the abdominal pain,~* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic, psychiatric or any disease that may interfere with the subject successfully completing the trial~* Hepatic dysfunction (ALT \[SGPT\] or AST \[SGOT\] \>3 times the upper limit of normal) or renal impairment (serum creatinine \> 2mg/dL)~* Has disease affecting electrolytes balance, such as SIADH with serum Sodium less than 130mmol/L~* Any evidence of or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year~* Any surgery on the stomach, small intestine or colon, excluding appendectomy~* A major psychiatric disorder (DSM-III-R or DSM-IV) including major depression or other psychoses that has required hospitalization in the last 1 year.~* History of attempted suicide or uncontrolled bipolar disorder.~* Currently using antidepressants for psychiatric conditions like major depression. Use of TCA or SSRI class antidepressant acceptable if being used specifically for treatment of bowel symptoms and patient is willing to taper off the medication~* Previous use of Milnacipran or other SNRI antidepressant (duloxetine, venlafaxine, desvenlafaxine)~* A diagnosis of seizure disorder~* A diagnosis of glaucoma~* Currently taking heparin or warfarin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Group A (50mg - 100mg) (Type: EXPERIMENTAL): Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
- Group B (50mg x12) (Type: ACTIVE_COMPARATOR): Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
- Group C (Placebo - 50mg) (Type: PLACEBO_COMPARATOR): Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TMS in Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of IBD, demonstrated to be in endoscopic remission (Mayo Endoscopic Subscore \[for UC\] 0 or 1, or Simple Endoscopic Score for CD ≤4) or biomarker remission (fecal calprotectin \<250 ug/g) within 6 months of randomization~* ≥8 on the Hospital Anxiety and Depression Scale~* on stable IBD-related and psychotropic medications for the four weeks preceding randomization~Exclusion Criteria:~* severely active IBD (Mayo score \> 9, HBI \> 16)~* require systemic corticosteroids~* initiated biologic treatment within the preceding three months~* suicidal ideation~* psychosis~* having failed ECT~* previous rTMS treatment (for blinding integrity)~* contraindications for MRI~* Use of benzodiazepines or GABA agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active iTBS rTMS (Type: ACTIVE_COMPARATOR): The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) twice daily for two weeks (20 sessions). The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
- Sham iTBS rTMS (Type: SHAM_COMPARATOR): sham rTMS treatment involves scalp stimulation with no magnetic pulse twice daily for two weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues